BiotechTube

Nab-paclitaxel in combination with pyrotinib

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Early Breast Cancer

Conditions

Early Breast Cancer

Trial Timeline

Jan 1, 2021 → Jun 1, 2025

NCT ID
NCT04659499

About Nab-paclitaxel in combination with pyrotinib

Nab-paclitaxel in combination with pyrotinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Early Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04659499. Target conditions include Early Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04659499Phase 2UNKNOWN

Competing Products

20 competing products in Early Breast Cancer

See all competitors
ProductCompanyStageHype Score
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25
Anastrozole + Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Fezolinetant + PlaceboAstellas PharmaPhase 2
52
Lecanemab IV + Placebo + Lecanemab SCEisaiPhase 3
77
E2609EisaiPhase 1
33
Doxorubicin + Cyclophosphamide + Taxane + Letrozole + Abemaciclib + LHRH AnalogueEli LillyPhase 2
52
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
77
ICGJohnson & JohnsonPre-clinical
23
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
77
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tabletsJiangsu Hengrui MedicinePhase 2
52
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
77
Adalimumab + Methotrexate + Adalimumab placebo + Methotrexate placeboAbbViePhase 3
77
adalimumab + methotrexateAbbViePhase 3
77
Camizestrant + Tamoxifen + Anastrozole + Letrozole + ExemestaneAstraZenecaPhase 3
77
Camizestrant + Tamoxifen + Anastrozole + Letrozole + Exemestane + AbemaciclibAstraZenecaPhase 3
77
Tamoxifen alone + Tamoxifen + AminoglutethimideAstraZenecaPhase 3
77
Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + TamoxifenAstraZenecaPhase 3
77
Trastuzumab deruxtecan + Standard-of-CareAstraZenecaPhase 2
52
DurvalumabAstraZenecaPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85